key: cord-0828935-mmt13tyf
authors: Ceriello, Antonio
title: Diabetes, SARS-CoV-2/COVID-19 vaccines and glycemic control: call for data
date: 2021-03-05
journal: Diabetes Res Clin Pract
DOI: 10.1016/j.diabres.2021.108741
sha: ee493fe3bb911a5160307b614a9c656887b91b5c
doc_id: 828935
cord_uid: mmt13tyf

nan

Immuno-response.

The prognosis of people with diabetes affected by COVID-19 is particularly bad (1).

There are several possible pathophysiological explanations, including the direct damaging effect of hyperglycemia (2), but, certainly, and hampered immune response, often present in this population, also plays a key role (3) (4) .

This reality raises the claim for prioritizing the vaccination against SARS-CoV-2/COVID-19 in people with diabetes (5).

The question, however, might be more complex. The goal of the vaccination is to obtain a sustained and effective immune response. In the case of diabetes the data is controversial, suggesting that not always this result is obtained (6) (7) . Evidence suggests that the glycemic control has a strong impact on the efficiency of the immune response (8) (9) . Therefore, it seems reasonable wondering whether it is not appropriate to improve glycemic control before administering the vaccine to optimize the response to it. Data is needed not to waste this important opportunity to get out of the pandemic for people with diabetes.

COVID-19 in people living with diabetes: An international consensus

Hyperglycemia and COVID-19: What was known and what is really new?

Type 2 diabetes and viral infection; cause and effect of disease

COVID-19 vaccine prioritisation for type 1 and type 2 diabetes

Benefits of flu vaccination for persons with diabetes mellitus: A review

Posthoc analysis of a randomized controlled trial: Diabetes mellitus modifies the efficacy of the 13-valent pneumococcal conjugate vaccine in elderly

Handicaps to host defense. Effects of hyperglycemia on C3 and Candida albicans

High glucose concentration impairs ATP outflow and immunoglobulin production by human peripheral B lymphocytes: involvement of P2X7 receptor

Conflict of Interest: AC does not have conflicts of interest to declare.